Suchergebnisse - "Herzer, Kerstin"

PubPharm (6)

1

The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2018

von Frey, A. | Piras-Straub, K. | Walker, A. | +3

2

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation : The Phase II SATURN study

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2017

von Forns, X. | Berenguer, M. | Herzer, K. | +16

3

Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease

enthalten in: Transplant international : official journal of the European Society for Organ Transplantation | 2017

von Herzer, K. | Welzel, T. | Spengler, U. | +9

CommentIn: Transpl Int. 2017 Mar;30(3):239-242. - PMID 28102906

4

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

enthalten in: Gut | 2016

von Welzel, T. | Petersen, J. | Herzer, K. | +12

CommentIn: Gut. 2017 Oct;66(10 ):1868-1869. - PMID 28073889

5

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection

enthalten in: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society | 2016

von Fontana, R. | Brown, R. | Moreno-Zamora, A. | +27

6

Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant

enthalten in: Digestion | 2015

von Herzer, K. | Papadopoulos-Köhn, A. | Walker, A. | +5

1
[1]